Vaccination With Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor by Adenoviral-Mediated Gene Transfer Augments Antitumor Immunity in Patients With Metastatic Melanoma
- 1 September 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (17) , 3343-3350
- https://doi.org/10.1200/jco.2003.07.005
Abstract
Purpose: Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) by retroviral-mediated gene transfer generates potent antitumor immunity in patients with metastatic melanoma. Further clinical development of this immunization scheme requires simplification of vaccine manufacture. We conducted a phase I clinical trial testing the biologic activity of vaccination with irradiated, autologous melanoma cells engineered to secrete GM-CSF by adenoviral-mediated gene transfer.Keywords
This publication has 38 references indexed in Scilit:
- A Universal Granulocyte-Macrophage Colony-Stimulating Factor-Producing Bystander Cell Line for Use in the Formulation of Autologous Tumor Cell-Based VaccinesHuman Gene Therapy, 1999
- Gene Therapy for Metastatic Brain Tumors by Vaccination with Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Tumor CellsHuman Gene Therapy, 1997
- A Phase I Study of Vaccination with Autologous, Irradiated Melanoma Cells Engineered to Secrete Human Granulocyte-Macrophage Colony Stimulating Factor. Dana-Farber Cancer Institute, Boston, MassachusettsHuman Gene Therapy, 1997
- Human tumor antigens recognized by T lymphocytes.The Journal of Experimental Medicine, 1996
- Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor AntigensScience, 1994
- Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma VaccineAnnals of Surgery, 1992
- Model Predicting Survival in Stage I Melanoma Based on Tumor ProgressionJNCI Journal of the National Cancer Institute, 1989
- Stage II malignant melanoma: Presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patientsJournal of Surgical Oncology, 1988
- Trans-activation of human immunodeficiency virus occurs via a bimodal mechanismCell, 1986
- A New Immunologic Marker for Human Langerhans CellsNew England Journal of Medicine, 1981